Literature DB >> 7050561

Hydralazine and related compounds: chemistry, metabolism, and mode of action.

P A Reece.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7050561     DOI： 10.1002/med.2610010105

Source DB:  PubMed          Journal:  Med Res Rev        ISSN： 0198-6325            Impact factor:   12.944


× No keyword cloud information.
  15 in total

Review 1.  Acrolein-mediated injury in nervous system trauma and diseases.

Authors:  Riyi Shi; Todd Rickett; Wenjing Sun
Journal:  Mol Nutr Food Res       Date:  2011-08-08       Impact factor: 5.914

2.  Hydralazine modifies Aβ fibril formation and prevents modification by lipids in vitro.

Authors:  Mukesh Maheshwari; Jessica K Roberts; Brent Desutter; Karen T Duong; Joseph Tingling; Janelle N Fawver; Hayley E Schall; Michael Kahle; Ian V J Murray
Journal:  Biochemistry       Date:  2010-11-17       Impact factor: 3.162

Review 3.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

4.  Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.

Authors:  P A Reece; I Cozamanis; R Zacest
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.

Authors:  Lyrialle W Han; Rachel J Ryu; Michael Cusumano; Thomas R Easterling; Brian R Phillips; Linda J Risler; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2019-06-30       Impact factor: 3.126

6.  Neuroprotective role of hydralazine in rat spinal cord injury-attenuation of acrolein-mediated damage.

Authors:  Jonghyuck Park; Lingxing Zheng; Andrew Marquis; Michael Walls; Brad Duerstock; Amber Pond; Sasha Vega-Alvarez; He Wang; Zheng Ouyang; Riyi Shi
Journal:  J Neurochem       Date:  2013-12-15       Impact factor: 5.372

7.  Disposition and pharmacokinetics of cadralazine and individual metabolites in man.

Authors:  H Schütz; J W Faigle; W Küng; W Theobald
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

8.  Mitigation of sensory and motor deficits by acrolein scavenger phenelzine in a rat model of spinal cord contusive injury.

Authors:  Zhe Chen; Jonghyuck Park; Breanne Butler; Glen Acosta; Sasha Vega-Alvarez; Lingxing Zheng; Jonathan Tang; Robyn McCain; Wenpeng Zhang; Zheng Ouyang; Peng Cao; Riyi Shi
Journal:  J Neurochem       Date:  2016-05-16       Impact factor: 5.372

Review 9.  Drug delivery, cell-based therapies, and tissue engineering approaches for spinal cord injury.

Authors:  Shushi Kabu; Yue Gao; Brian K Kwon; Vinod Labhasetwar
Journal:  J Control Release       Date:  2015-09-04       Impact factor: 9.776

10.  Evaluation of once daily endralazine in hypertension.

Authors:  R Wu; J D Spence; S G Carruthers
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.